Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I, First-in-human, Dose Escalation Study Of [225Ac]-AZD2284 in Patients With Metastatic Castration-Resistant Prostate Cancer

NCT06879041 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT06879041
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06879041 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I, First-in-human, Dose Escalation Study Of [225Ac]-AZD2284 in Patients With Metastatic Castration-Resistant Prostate Cancer
Lead sponsor
AstraZeneca
Phase
Phase 1
Overall status
Recruiting
Start date
March 10, 2025
Completion date
April 16, 2029
Enrollment
136 (estimated)
Sites
16

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic castration-resistant prostate cancer